NCT02477059View on ClinicalTrials.gov

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

December 26, 2018

Study Completion Date

February 28, 2019

Conditions
Hand Osteoarthritis
Interventions
DRUG

tocilizumab

Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.

DRUG

saline solution

La saline solution is administered by intravenous infusion.

Trial Locations (1)

75010

Rheumatology department Lariboisiere Hospital, Paris

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02477059 - Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis | Biotech Hunter | Biotech Hunter